Viusid

Viusid is a multi-ingredient nutritional supplement developed by Catalysis Laboratories, primarily marketed for its antioxidant and immunomodulatory properties. Its formulation includes glycyrrhizic acid (derived from licorice root), glucosamine, amino acids (arginine, glycine), vitamins (ascorbic acid, pyridoxine, folic acid, cyanocobalamin, calcium pantothenate), and minerals (zinc sulfate). The supplement is processed using a molecular activation technique intended to enhance the biological activity of its components. Viusid has been extensively studied in clinical trials as an adjuvant therapy for chronic viral infections such as Hepatitis C, HPV, and COVID-19, as well as for liver diseases like cirrhosis and nonalcoholic steatohepatitis (NASH). Additionally, it is investigated for its potential to improve quality of life and reduce chemotherapy-induced toxicity in patients with various malignancies, including gastric, prostate, and colorectal cancers. Its mechanism of action involves the modulation of cytokine production—specifically increasing anti-inflammatory cytokines like IL-10 and IFN-gamma while stabilizing TNF-alpha—and the reduction of oxidative stress through the neutralization of reactive oxygen species.

Brand names

Viusid

Other names

Viusid oral solutionViusid nutritional supplement